Funding:

Immunic AG

Description

Following a 4-week screening period, participants will take either oral IMU-838 or placebo for a period of 72 weeks during the main period of the study. Participants may need to stop taking certain MS medications during the trial.  An MRI scan will be needed during screening period for eligibility assessment, and then three additional times during the main period. A visual acuity test, a walk test, and an arm function test are performed at screening. Blood and urine samples and electrocardiograms will be taken during the study. MS symptoms will be assessed by investigator at each visit. There will NOT be any spinal taps during the trial.